NEW BRUNSWICK, N.J. / May 10, 2023 / Business Wire / Johnson & Johnson (NYSE: JNJ) will participate in the Goldman Sachs 44th Annual Global Healthcare Conference on Tuesday, June 13th, at the Waldorf Astoria Monarch Beach Resort & Club in Dana Point, CA. Biljana Naumovic, Worldwide Vice President, Oncology, and Peter Lebowitz, Global Therapeutic Head, Oncology, will represent the Company in a session scheduled at 4:20 p.m. (Eastern Time).
This webcast will be available to investors and other interested parties by accessing the Johnson & Johnson website at www.investor.jnj.com.
A webcast replay will be available approximately 48-hrs after the live webcast.
| Last Trade: | US$157.47 |
| Daily Change: | 3.56 2.31 |
| Daily Volume: | 10,586,239 |
| Market Cap: | US$379.500B |
April 15, 2025 April 02, 2025 | |
Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MORE
Compass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...
CLICK TO LEARN MORE
